Brenig Therapeutics launches first-in-human trial of novel neurodegenerative therapy
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
India plays a critical role in Bristol Myers Squibb’s global strategy
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
The initiative aims to connect startups and tech companies with its business units,
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
Subscribe To Our Newsletter & Stay Updated